Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the management of hematologic and non-hematologic toxicities in cancer patients, emphasizing the importance of proactive monitoring and collaboration between clinicians and pharmacists.

Michael Fifer, MD, discusses the Maple HCM study, which compared the cardiac myosin inhibitor Aficamten and the beta blocker Metoprolol in patients with obstructive hypertrophic cardiomyopathy (HCM).

ChatGPT said: Crystal Hodge, PharmD, BCIDP, BCPS, emphasized that declining vaccination rates below the 95% herd immunity threshold have fueled recent measles outbreaks, underscoring the urgent need for pharmacist-led vaccination advocacy.

Legislative efforts aim to improve oncology medication access, addressing transportation barriers and advocating for mail delivery from cancer clinics.

Elizabeth Vaughan, MD, MPH, RD, highlights how pharmacists can build patient trust, encourage vaccination, and use simple strategies to spark conversations with hesitant individuals.

Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early side effect management for patients starting zongertinib (Hernexeos).

Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).

Elizabeth Vaughan, MD, MPH, RD, addresses how state-level differences and potential new prescription requirements could impact patient access to COVID-19 vaccines this fall.

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the challenges of managing myelofibrosis, from its heterogeneity and symptom burden to limited curative options.